---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003248"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:22:27.824510+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Silexion selects CRO AMS for SIL204 Phase 2/3 trials; H1 2026 start expected

## Summary
- CRO AMS has over 28 years of drug development experience and Phase 3 oncology trial expertise.
- Regulatory submissions planned for Q4 2025 (Israel) and Q1 2026 (EU).
- Phase 2/3 clinical trials for SIL204 expected to commence in first half of 2026.
- SIL204 previously showed up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations.

## SEC filing metadata
- accession: 0001178913-25-003248
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003248/0001178913-25-003248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003248/zk2533756.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003248
- JSON: https://secwatch.observer/filing/0001178913-25-003248.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.